TransCode Therapeutics, Inc.
RNAZ
$8.95
-$0.34-3.66%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -15.41% | 73.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.06% | 33.11% | |||
| Operating Income | -8.06% | -33.11% | |||
| Income Before Tax | -13.55% | 64.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.55% | 64.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.55% | 64.61% | |||
| EBIT | -8.06% | -33.11% | |||
| EBITDA | -8.29% | -33.25% | |||
| EPS Basic | -13.55% | 92.69% | |||
| Normalized Basic EPS | -13.55% | 92.69% | |||
| EPS Diluted | -13.55% | 92.69% | |||
| Normalized Diluted EPS | -13.55% | 92.69% | |||
| Average Basic Shares Outstanding | 0.00% | 383.87% | |||
| Average Diluted Shares Outstanding | 0.00% | 383.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||